{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:57:44Z","timestamp":1781121464437,"version":"3.54.1"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Peripheral arterial disease patients undergoing lower limb revascularization remain at high risk of thrombotic complications, yet optimal postprocedural antithrombotic therapy remains uncertain. Current strategies vary widely, reflecting the difficulty of balancing ischemic protection against bleeding risk. This review critically examines the evidence supporting antithrombotic approaches after lower limb revascularization and explores whether contemporary practice is characterized by overtreatment, undertreatment, or both. Randomized controlled trials, subgroup analyses, and recent meta-analyses evaluating dual pathway inhibition (DPI), dual antiplatelet therapy (DAPT), and single antiplatelet therapy were reviewed, with particular attention to efficacy, safety, treatment duration, and patient selection. DPI is supported by robust randomized evidence demonstrating reductions in major adverse cardiovascular and limb events, particularly after revascularization. In contrast, DAPT remains widely used despite limited and methodologically heterogeneous evidence. Available meta-analyses suggest potential reductions in myocardial infarction, cardiac mortality, and reintervention with DAPT compared with single antiplatelet therapy, although certainty remains low and no randomized trial has directly compared DAPT with DPI. This evidentiary gap contributes to a clinical paradox in which some patients receive prolonged combination therapy with excess bleeding risk, whereas others at particularly high ischemic risk may remain undertreated. Current guideline-based approaches insufficiently account for procedural complexity, patient phenotype, and temporal changes in thrombotic risk. A more personalized and dynamic antithrombotic strategy is needed to optimize outcomes in peripheral arterial disease after revascularization.<\/jats:p>","DOI":"10.1097\/crd.0000000000001353","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:00:12Z","timestamp":1781118012000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic Therapy After Lower Limb EndoVascular Interventions: Are We Overtreating or Undertreating? \u2013 A Narrative Review"],"prefix":"10.1097","author":[{"given":"Antonio","family":"Bozzani","sequence":"first","affiliation":[{"name":"Vascular Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Destefanis Gallo","sequence":"additional","affiliation":[{"name":"Vascular Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Salzillo","sequence":"additional","affiliation":[{"name":"Vascular Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Arici","sequence":"additional","affiliation":[{"name":"Vascular Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Rossini","sequence":"additional","affiliation":[{"name":"Vascular Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Rota","sequence":"additional","affiliation":[{"name":"Vascular Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Visciglia","sequence":"additional","affiliation":[{"name":"Vascular Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"R1-20260610","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","article-title":"Epidemiology of peripheral artery disease and polyvascular disease.","volume":"128","author":"Aday","year":"2021","journal-title":"Circ Res"},{"key":"R2-20260610","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.ejvs.2023.03.042","article-title":"Editor\u2019s choice, european society for vascular surgery (ESVS) 2023 clinical practice guidelines on antithrombotic therapy for vascular diseases.","volume":"65","author":"Twine","year":"2023","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R3-20260610","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease.","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ Res"},{"key":"R4-20260610","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1055\/s-0031-1278244","article-title":"Peripheral arterial disease: epidemiology, natural history, diagnosis and treatment.","volume":"16","author":"Dhaliwal","year":"2007","journal-title":"Int J Angiol"},{"key":"R5-20260610","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3390\/ph15050596","article-title":"Mono or dual antiplatelet therapy for treating patients with peripheral artery disease after lower extremity revascularization: a systematic review and meta-analysis.","volume":"15","author":"Tsai","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"R6-20260610","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jcin.2019.08.006","article-title":"Optimal strategy for antiplatelet therapy after endovascular revascularization for lower extremity peripheral artery disease.","volume":"12","author":"Cho","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"R7-20260610","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1161\/CIRCULATIONAHA.117.029834","article-title":"Improving 1-year outcomes of infrainguinal limb revascularization: population-based cohort study of 104 000 patients in England.","volume":"137","author":"Heikkila","year":"2018","journal-title":"Circulation"},{"key":"R8-20260610","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/1538574413510619","article-title":"Neck-targeted, stand-alone coiling for successful treatment of type 1A endoleak following endovascular repair.","volume":"48","author":"Arici","year":"2014","journal-title":"Vasc Endovascular Surg"},{"key":"R9-20260610","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCULATIONAHA.123.067687","article-title":"Illness trajectories after revascularization in patients with peripheral artery disease: a unified approach to understanding the risk of major amputation and death.","volume":"150","author":"Li","year":"2024","journal-title":"Circulation"},{"key":"R10-20260610","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: a report of the American college of cardiology\/American Heart association joint committee on clinical practice guidelines.","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"key":"R11-20260610","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1161\/CIRCULATIONAHA.120.050465","article-title":"Rivaroxaban and aspirin in peripheral artery disease lower extremity revascularization: impact of concomitant clopidogrel on efficacy and safety.","volume":"142","author":"Hiatt","year":"2020","journal-title":"Circulation"},{"key":"R12-20260610","doi-asserted-by":"crossref","first-page":"368504251324332","DOI":"10.1177\/00368504251324332","article-title":"Single versus dual antiplatelet therapy impact on coagulation\/thrombosis post PAD revascularization.","volume":"108","author":"Rodriguez Alvarez","year":"2025","journal-title":"Sci Prog"},{"key":"R13-20260610","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.avsg.2019.10.040","article-title":"Contemporary early and long-term results of open repair for ruptured and symptomatic unruptured infrarenal AAA. single center experience.","volume":"64","author":"Arici","year":"2020","journal-title":"Ann Vasc Surg"},{"key":"R14-20260610","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/CIRCRESAHA.118.313141","article-title":"Synergy of dual pathway inhibition in chronic cardiovascular disease.","volume":"124","author":"Coppens","year":"2019","journal-title":"Circ Res"},{"key":"R15-20260610","doi-asserted-by":"crossref","first-page":"e032782","DOI":"10.1161\/JAHA.123.032782","article-title":"Quantitative benefit-risk evaluation of rivaroxaban in patients after peripheral arterial revascularization: the VOYAGER PAD trial.","volume":"13","author":"Yuan","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"R16-20260610","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3400\/avd.oa.24-00056","article-title":"Comparison of single antiplatelet therapy and dual antiplatelet therapy after endovascular therapy in patients with lower extremity artery disease.","volume":"17","author":"Yamada","year":"2024","journal-title":"Ann Vasc Dis"},{"key":"R17-20260610","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00330-012-2441-2","article-title":"Management of peripheral arterial interventions with mono or dual antiplatelet therapyethe MIRROR study: a randomised and double-blinded clinical trial.","volume":"22","author":"Tepe","year":"2012","journal-title":"Eur Radiol"},{"key":"R18-20260610","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jvs.2010.04.027","article-title":"Results of the randomized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial.","volume":"52","author":"Belch","year":"2010","journal-title":"J Vasc Surg"},{"key":"R19-20260610","first-page":"21","article-title":"Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial.","volume":"6","author":"Kaplovitch","year":"2021","journal-title":"JAMA Cardiol"},{"key":"R20-20260610","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/clc.23926","article-title":"Efficacy and safety of rivaroxaban versus placebo after lower extremity bypass surgery: a post hoc analysis of a \u201cCASPAR like\u201d outcome from VOYAGER PAD.","volume":"45","author":"Bonaca","year":"2022","journal-title":"Clin Cardiol"},{"key":"R21-20260610","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1001\/jamaneurol.2019.0072","article-title":"Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection: the cervical artery dissection in stroke study (CADISS) randomized clinical trial final results.","volume":"76","author":"Markus","year":"2019","journal-title":"JAMA Neurol"},{"key":"R22-20260610","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"R23-20260610","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1161\/01.CIR.0000163561.90680.1C","article-title":"Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) trial.","volume":"111","author":"Markus","year":"2005","journal-title":"Circulation"},{"key":"R24-20260610","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial.","volume":"71","author":"Anand","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R25-20260610","doi-asserted-by":"crossref","first-page":"e006399","DOI":"10.1161\/CIRCOUTCOMES.119.006399","article-title":"Incidence and factors associated with major amputation in patients with peripheral artery disease: insights from the EUCLID trial.","volume":"13","author":"Long","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"R26-20260610","first-page":"678","article-title":"Outcomes of patients with critical limb ischaemia in the EUCLID trial.","volume":"67","author":"Norgren","year":"2018","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R27-20260610","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1016\/j.jacc.2012.08.989","article-title":"ACHILLES investigators. a prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial.","volume":"60","author":"Scheinert","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R28-20260610","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1583\/13-4275MR.1","article-title":"Twelve-month results of a randomized trial comparing mono with dual antiplatelet therapy in endovascularly treated patients with peripheral artery disease.","volume":"20","author":"Strobl","year":"2013","journal-title":"J Endovasc Ther"},{"key":"R29-20260610","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jvs.2015.01.051","article-title":"Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.","volume":"62","author":"Armstrong","year":"2015","journal-title":"J Vasc Surg"},{"key":"R30-20260610","doi-asserted-by":"crossref","first-page":"802.e13","DOI":"10.1016\/j.avsg.2012.07.029","article-title":"Successful endovascular treatment of a bronchial artery aneurysm refractory to transcatheter embolization.","volume":"27","author":"Arici","year":"2013","journal-title":"Ann Vasc Surg"},{"key":"R31-20260610","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jvs.2016.05.098","article-title":"Society for vascular surgery vascular quality initiative. dual antiplatelet therapy is associated with prolonged survival after lower extremity revascularization.","volume":"64","author":"Soden","year":"2016","journal-title":"J Vasc Surg"},{"key":"R32-20260610","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.ejvs.2016.12.014","article-title":"Editor\u2019s choice \u2013 dual antiplatelet therapy improves outcome in diabetic patients undergoing endovascular femoropopliteal stenting for critical limb ischaemia.","volume":"53","author":"Thott","year":"2017","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R33-20260610","doi-asserted-by":"crossref","first-page":"e0234271","DOI":"10.1371\/journal.pone.0234271","article-title":"Single versus dual antiplatelet therapy following peripheral arterial endovascular intervention for chronic limb threatening ischaemia: retrospective cohort study.","volume":"15","author":"Chinai","year":"2020","journal-title":"PLoS One"},{"key":"R34-20260610","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.3390\/jcm9113515","article-title":"Short-term clinical outcomes of single versus dual antiplatelet therapy after infrainguinal endovascular treatment for peripheral arterial disease.","volume":"9","author":"Ipema","year":"2020","journal-title":"J Clin Med"},{"key":"R35-20260610","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jvs.2020.06.127","article-title":"Effects of dual antiplatelet therapy on graft patency after lower extremity bypass.","volume":"73","author":"Belkin","year":"2021","journal-title":"J Vasc Surg"},{"key":"R36-20260610","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1001\/jamacardio.2016.2811","article-title":"Prolonged vs short duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with or without peripheral arterial disease: a subgroup analysis of the PRODIGY randomized clinical trial.","volume":"1","author":"Franzone","year":"2016","journal-title":"JAMA Cardiol"},{"key":"R37-20260610","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/17085381241237005","article-title":"Optimizing platelet inhibition in peripheral artery disease: a comparison of mono-antiplatelet therapy and dual-antiplatelet therapy using thromboelastography.","volume":"33","author":"Lee","year":"2025","journal-title":"Vascular"},{"key":"R38-20260610","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1016\/j.jacc.2024.04.003","article-title":"2024 Lower extremity peripheral artery disease guideline-at-a-glance.","volume":"83","author":"Bates","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"R39-20260610","first-page":"47","article-title":"Bleeding risk in patients with peripheral arterial disease.","volume":"13","author":"Vison\u00e0","year":"2022","journal-title":"Life (Basel)"},{"key":"R40-20260610","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1177\/1358863X18820123","article-title":"Antithrombotics in stable peripheral artery disease.","volume":"24","author":"Kaplovitch","year":"2019","journal-title":"Vasc Med"},{"key":"R41-20260610","doi-asserted-by":"crossref","first-page":"102249","DOI":"10.1016\/j.cpcardiol.2023.102249","article-title":"Spatio-temporal correlation between admissions for ruptured abdominal aortic aneurysms and levels of atmospheric pollution in Italy.","volume":"49","author":"Bozzani","year":"2024","journal-title":"Curr Probl Cardiol"},{"key":"R42-20260610","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.jvs.2023.07.069","article-title":"New candidates for screening of abdominal aortic aneurysm outside of current guidelines.","volume":"79","author":"Bozzani","year":"2024","journal-title":"J Vasc Surg"},{"key":"R43-20260610","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"R44-20260610","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1056\/NEJMoa1401105","article-title":"Aspirin in patients undergoing noncardiac surgery.","volume":"370","author":"Devereaux","year":"2014","journal-title":"N Engl J Med"},{"key":"R45-20260610","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1056\/NEJMoa1200933","article-title":"Vorapaxar in the secondary prevention of atherothrombotic events.","volume":"366","author":"Morrow","year":"2012","journal-title":"N Engl J Med"},{"key":"R46-20260610","first-page":"368","article-title":"Rivaroxaban in peripheral artery disease after revascularization.","volume":"72","author":"Bonaca","year":"2020","journal-title":"N Engl J Med"},{"key":"R47-20260610","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.jvs.2022.05.023","article-title":"Adapting guidelines for elective repair of asymptomatic abdominal aortic aneurysms.","volume":"76","author":"Bozzani","year":"2022","journal-title":"J Vasc Surg"},{"key":"R48-20260610","doi-asserted-by":"crossref","first-page":"103151","DOI":"10.1016\/j.cpcardiol.2025.103151","article-title":"Inflammation, abdominal aortic aneurysm enlargement and rupture. Lessons learned from the Covid19 pandemic.","volume":"50","author":"Sterpetti","year":"2025","journal-title":"Curr Probl Cardiol"},{"key":"R49-20260610","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1056\/NEJMoa065959","article-title":"Oral anticoagulant and antiplatelet therapy and peripheral arterial disease.","volume":"357","author":"Anand","year":"2007","journal-title":"N Engl J Med"},{"key":"R50-20260610","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ejvs.2021.12.019","article-title":"The OAC3-PAD risk score predicts major bleeding events at one year after hospitalisation for peripheral artery disease.","volume":"63","author":"Behrendt","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R51-20260610","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejvs.2021.09.026","article-title":"A systematic review and meta-analysis on the impact of high on-treatment platelet reactivity on clinical outcomes for patients taking ADP receptor inhibitors following lower limb arterial endovascular intervention.","volume":"63","author":"Zlatanovic","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R52-20260610","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejvs.2022.07.008","article-title":"Antithrombotic therapy for aortic and peripheral artery aneurysms: a systematic review and meta-analysis.","volume":"64","author":"Wong","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R53-20260610","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ejvs.2023.08.070","article-title":"A new way to look at screening for aortic aneurysms.","volume":"67","author":"Sterpetti","year":"2024","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R54-20260610","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1093\/eurheartj\/ehab390","article-title":"Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombosis, and the ESC working group on cardiovascular pharmacotherapy.","volume":"42","author":"Aboyans","year":"2021","journal-title":"Eur Heart J"},{"key":"R55-20260610","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.1016\/j.jacc.2016.11.007","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines.","volume":"69","author":"Gerhard-Herman","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R56-20260610","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2020.11.001","article-title":"Polyvascular disease: a narrative review of current evidence and a consideration of the role of antithrombotic therapy.","volume":"315","author":"Weissler","year":"2020","journal-title":"Atherosclerosis"},{"key":"R57-20260610","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejvs.2021.05.028","article-title":"Editor\u2019s choice - external applicability of the COMPASS and VOYAGER-PAD trials on patients with symptomatic lower extremity artery disease in france: the COPART registry.","volume":"62","author":"Lap\u00e9bie","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R58-20260610","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejvs.2021.10.026","article-title":"Revascularisation for symptomatic peripheral artery disease: external applicability of the VOYAGER PAD trial.","volume":"63","author":"S\u00f8gaard","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R59-20260610","doi-asserted-by":"crossref","first-page":"e0175283","DOI":"10.1371\/journal.pone.0175283","article-title":"Efficacy and safety of aspirin in patients with peripheral vascular disease: an updated systematic review and meta-analysis of randomized controlled trials.","volume":"12","author":"Mahmoud","year":"2017","journal-title":"PLoS One"},{"key":"R60-20260610","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1001\/jama.2018.5422","article-title":"Antithrombotic therapy for peripheral artery disease in 2018.","volume":"319","author":"Hess","year":"2018","journal-title":"JAMA"},{"key":"R61-20260610","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/bjs.9592","article-title":"Risk of bleeding and adverse outcomes predicted by thromboelastography platelet mapping in patients taking clopidogrel within 7 days of non-cardiac surgery.","volume":"101","author":"Kasivisvanathan","year":"2014","journal-title":"Br J Surg"},{"key":"R62-20260610","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1055\/s-0038-1641153","article-title":"Platelet inhibition and bleeding in patients undergoing non-cardiac surgery-the BIANCA observational study.","volume":"118","author":"Mahla","year":"2018","journal-title":"Thromb Haemost"},{"key":"R63-20260610","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.ejvs.2022.07.050","article-title":"Association between peri-operative aspirin resistance and cardiovascular outcome (POPART-CVO): a prospective non-interventional cohort study.","volume":"64","author":"Dehne","year":"2022","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R64-20260610","first-page":"753","article-title":"Impact of preoperative use of P2Y12 receptor inhibitors on clinical outcomes in cardiac and noncardiac surgery: a systematic review and meta-analysis.","volume":"6","author":"Siller-Matula","year":"2017","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R65-20260610","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/jth.12538","article-title":"Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis.","volume":"12","author":"Wisman","year":"2014","journal-title":"J Thromb Haemost"},{"key":"R66-20260610","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0140-6736(21)00533-X","article-title":"Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.","volume":"397","author":"Galli","year":"2021","journal-title":"Lancet"},{"key":"R67-20260610","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11886-019-1198-5","article-title":"Rivaroxaban and aspirin in peripheral vascular disease: a review of implementation strategies and management of common clinical scenarios.","volume":"21","author":"McClure","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"R68-20260610","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/ehjcvp\/pvz036","article-title":"Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology working group on cardiovascular pharmacotherapy in collaboration with the European Society of Cardiology Working Group on aorta and peripheral vascular diseases.","volume":"6","author":"Savarese","year":"2020","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"R69-20260610","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2174\/1570161118666200820141131","article-title":"Efficacy and safety of antiplatelet therapies in symptomatic peripheral artery disease: a systematic review and network meta-analysis.","volume":"19","author":"De Carlo","year":"2021","journal-title":"Curr Vasc Pharmacol"},{"key":"R70-20260610","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ejvs.2021.05.038","article-title":"Network meta-analysis of the benefit of aspirin with rivaroxaban vs. clopidogrel for patients with stable symptomatic lower extremity arterial disease.","volume":"62","author":"Ambler","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"R71-20260610","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jacc.2018.07.046","article-title":"Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial.","volume":"72","author":"Baumgartner","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R72-20260610","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1177\/1526602818760488","article-title":"Edoxaban plus aspirin vs dual antiplatelet therapy in endovascular treatment of patients with peripheral artery disease: results of the ePAD trial.","volume":"25","author":"Moll","year":"2018","journal-title":"J Endovasc Ther"},{"key":"R73-20260610","doi-asserted-by":"crossref","first-page":"8561350","DOI":"10.1155\/2021\/8561350","article-title":"Efficacy and safety of rivaroxaban compared with other therapies used in patients with peripheral artery disease undergoing peripheral revascularization: a systematic literature review and network meta-analysis.","volume":"2021","author":"Bauersachs","year":"2021","journal-title":"Cardiovasc Ther"},{"key":"R74-20260610","first-page":"CD000535","article-title":"Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.","volume":"2015","author":"Bedenis","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"R75-20260610","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.athoracsur.2007.05.077","article-title":"Endovascular treatment of acute type B dissection and kommerell\u2019s diverticulum.","volume":"84","author":"Odero","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"R76-20260610","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1089\/scd.2013.0172","article-title":"Allogeneic lethally irradiated cord blood mononuclear cells in no-option critical limb ischemia: a box of rain.","volume":"22","author":"Perotti","year":"2013","journal-title":"Stem Cells Dev"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:00:20Z","timestamp":1781118020000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":76,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001353","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}